Overall, only 2.0% of the patient population studied received first diagnosis of depression during the 2-year follow-up period and the study reported no significant differences in the incidence of depression in patients who received anti-VEGF treatments compared with those who did not. The gene discussed is VEGFA; the disease is depressive symptom measurement.